Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Companion Diagnostics

Jonathan Pan's Biography



Jonathan Pan, Director, GlaxoSmithKline Oncology

Jonathan L. Pan, PhD, heads the oncology companion diagnostic and disease strategy within GSK Oncology. In his role, he works closely with diagnostic stakeholders globally, particularly pathologists, oncologists, payors, and policy makers to ensure that diagnostic testing is not a barrier to appropriate therapeutic treatments. His focus is on both currently marketed therapeutics as well as pipeline products to ensure that the proper diagnostic infrastructure is in place in different markets. Prior to joining GSK, Jonathan helped to establish the pharmaceutical practice at Scientia Advisors, a boutique consulting firm in Boston. There, he worked on innovation, portfolio, and competitive strategies for pharmaceutical, medical device, and diagnostic companies – looking at unique synergies and opportunities to engage the market. In addition, Jonathan was a senior consultant on IMS Consulting Groups’ Product and Portfolio Strategy team as well as a consultant on Deloitte’s Consulting Enterprise Risk Strategy team, servicing federal clients such as the Nuclear Regulatory Commission, Health and Human Services, and Department of Education. Jonathan also has experience in due diligence working in the middle markets for large private equity providing leveraged buy-out options or mezzanine financing. Jonathan is a proud University of Michigan graduate earning his PhD in cellular and molecular biology and an MBA in management.

Jonathan Pan Image

Crossing the Chasm to Companion Diagnostic Commercialization

Monday, 27 October 2014 at 09:45

Add to Calendar ▼2014-10-27 09:45:002014-10-27 10:45:00Europe/LondonCrossing the Chasm to Companion Diagnostic CommercializationSELECTBIOenquiries@selectbiosciences.com

The development of a companion diagnostic and the evolving regulatory aspects has been of considerable discussion and advancement over the past several years.  An underrepresented area has been the commercialization of the companion diagnostic where several assumptions have proven to be invalid.  In this talk, we shift gears to talk about the commercialization of companion diagnostics, using historical case examples and new insights, looking at the different aspects of access:

•    Commercial Dynamics
•    Reimbursement
•    Sales and Marketing


Add to Calendar ▼2014-10-27 00:00:002014-10-28 00:00:00Europe/LondonCompanion DiagnosticsSELECTBIOenquiries@selectbiosciences.com